The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: 0.50 (2.86%)
Spread: 1.00 (5.714%)
Open: 17.50
High: 18.00
Low: 17.50
Prev. Close: 17.50
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of LeanBiome in Muscletech

15 Jan 2024 07:00

RNS Number : 5934Z
OptiBiotix Health PLC
15 January 2024
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Launch of LeanBiome® in Muscletech®

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare announces the forthcoming launch of LeanBiome® in Muscletech®, one of the leading sports nutrition brands in the industry and backed by America's No. 1 selling sports supplement company (see About Us · MuscleTech). The product is currently being advertised on social media by the Company's partner ahead of online and instore launches with multiple retailers in Sweden, France, Poland, Germany, the Netherlands, Greece and the UK - see https://www.stack3d.com/2024/01/muscletech-nitro-tech-ripped-europe.html 

 

Muscletech® is known as a leading brand in the science nutrition space recognised for its research with scientific experts to identify and utilise science backed ingredients in their products to bring unique benefits to athletes and fitness enthusiasts around the world. LeanBiome® will be incorporated in Muscletech Nitro Tech Ripped range, a premium protein powder designed to support athletes who want to lose fat and build lean muscle and will be launched in Europe and the United Kingdom across multiple e-commerce sites and distribution channels.

 

LeanBiome® is a scientifically formulated sports nutrition ingredient which has been developed by OptiBiotix to support athletes seeking to increase lean muscle mass and to change their body composition. LeanBiome® contains a patented combination of fibres, prebiotics and minerals developed to increase the microbiome diversity of athletes on a high protein diet. A diverse microbiome is important in harvesting essential nutrients from the diet and has been linked to improved health and wellbeing and increased resilience to disease. Many researchers now believe that a diverse microbiome is an essential factor in achieving physical fitness, which was previously thought to be achievable solely through a healthy diet and regular exercise. This is supported by the growing scientific evidence of a link between the microbiome and athletic performance which suggest that optimizing an athletes gut microbiome could improve and athletes stamina, lower inflammation, and support physical fitness (Frontiers | Editorial: Nutrition to support gut health and the microbiome in athletes (frontiersin.org)

 

 

Stephen OHara, CEO of OptiBiotix Health plc commented: "We are very pleased to announce the launch of LeanBiome® with such a well-known and internationally respected sports brand such as Muscletech®. LeanBiome® has been formulated to support anyone interested in improving their fitness for leisure or the elite athlete. It is supported by multiple published clinical studies which show it helps reduce body fat around the waist and hips, improving body leanness whilst enhancing the diversity of the gut microbiome to improve stamina and overall fitness.

 

"LeanBiome® is a unique product which is increasingly being recognised by major sports brands as a key differentiator from existing products and has the potential to have a major impact in the sports nutrition and health and fitness markets."

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

Peterhouse Capital Limited (Broker)

Tel: 020 7220 9797

Duncan Vasey / Lucy Williams

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

About OptiBiotix www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBTMFTMTJBBBI
Date   Source Headline
4th Jul 20182:07 pmRNSResult of AGM
4th Jul 20187:00 amRNSDirectorate Change
26th Jun 20187:00 amRNSAgreement with global corporate for SweetBiotix®
21st Jun 20187:00 amRNSExclusive license agreement for LPLDL®
18th Jun 20187:00 amRNSManufacturing agreement with Morley Foods
14th Jun 20187:00 amRNSExercise of Options and Issue of Equity
11th Jun 20187:00 amRNSNotice of AGM
7th Jun 20187:00 amRNSUS launch of LPLDL® with Seed Health
31st May 20187:00 amRNSSweetBiotix® agreement with global dairy company
30th May 20187:00 amRNSPlacing and Issue of Equity
23rd May 20187:00 amRNSFinal Results
22nd May 20187:00 amRNSLP-LDL agreement for USA
18th May 20187:00 amRNSSlimBiome® wins award at Vitafoods 2018
16th May 20184:40 pmRNSHolding(s) in Company
16th May 20187:00 amRNSExclusive manufacturing and supply agreement
8th May 20187:00 amRNSLaunch of extended range of products at Vitafoods
1st May 20187:00 amRNSLP-LDL? news media interest in USA
30th Apr 20187:00 amRNSNotice of Results
24th Apr 20187:00 amRNSSlimBiome non-exclusive UK distribution agreement
19th Apr 20187:00 amRNSAppointment of Head of Online Sales and Marketing
18th Apr 20187:00 amRNSCholBiome exclusive distribution agreement
5th Apr 20187:00 amRNSNew patent filings for SweetBiotix
27th Mar 20187:00 amRNSScientific and commerical update
8th Mar 20187:00 amRNSLaunch of Slimbiome in Nutri-bites
6th Mar 20187:00 amRNSLPLDL® Exclusive European License Agreement
28th Feb 20187:00 amRNSOptiBiotix Capital Reorganisation
6th Feb 20187:00 amRNSExercise of warrant and issue of equity
1st Feb 20182:22 pmRNSDirector's dealing
30th Jan 20183:03 pmRNSExercise of warrant and issue of equity
25th Jan 201811:45 amRNSResult of Meeting
23rd Jan 20187:00 amRNSSweetBiotix® development: human taste studies
17th Jan 20187:00 amRNSPresentation of data at European Conference
8th Jan 20183:12 pmRNSShareholder Circular and Notice of General Meeting
8th Jan 20187:00 amRNSDirectorate Changes
14th Dec 20173:35 pmRNSExercise of warrant and issue of equity
12th Dec 20177:00 amRNSManufacturing, supply & profit sharing agreement
5th Dec 20177:00 amRNSProposed directorate changes
28th Nov 20177:00 amRNSCapital reorganisation
17th Nov 20173:06 pmRNSExercise of Warrant and Issue of Equity
8th Nov 20177:00 amRNSSlimBiome® commercial & product development update
1st Nov 20177:00 amRNSManufacturing, supply & profit sharing agreement
26th Oct 20177:00 amRNSPresentation of research
24th Oct 20177:00 amRNSLPLDL® supply agreement with Galenicum
4th Oct 20177:00 amRNSSuccessful launch of products at Supply Side West
19th Sep 20177:00 amRNSTechnical, regulatory & commercial update
13th Sep 20177:00 amRNSStrategic partnership with Bened Biomedical
11th Sep 201712:00 pmRNSHolding(s) in Company
7th Sep 20177:00 amRNSInvited to present at Expoquimia in Barcelona
6th Sep 20179:30 amRNSInvestor evening
5th Sep 20177:00 amRNSManufacturing Agreement with Tata Chemicals

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.